CUE Stock Price, Cue Biopharma Inc Quote, Chart

Market Summary

USD1.42-0.08

Market Closed

-5.33%

CUE Stock Price

View Fullscreen

CUE RSI Chart

CUE Valuation

Market Cap

69.1M

Price/Earnings (Trailing)

-1.36

Price/Sales (Trailing)

12.58

EV/EBITDA

-0.71

Price/Free Cashflow

-1.73

CUE Price/Sales (Trailing)

CUE Profitability

EBT Margin

-965.58%

Return on Equity

-136.8%

Return on Assets

-82.45%

Free Cashflow Yield

-57.85%

CUE Fundamentals

CUE Revenue

Revenue (TTM)

5.5M

Rev. Growth (Yr)

1.1K%

Rev. Growth (Qtr)

-13.29%

CUE Earnings

Earnings (TTM)

-50.7M

Earnings Growth (Yr)

7.94%

Earnings Growth (Qtr)

-22.07%

Breaking Down CUE Revenue

Last 7 days

-12.9%

Last 30 days

-23.7%

Last 90 days

-47.4%

Trailing 12 Months

-61.3%

How does CUE drawdown profile look like?

CUE Financial Health

Current Ratio

3.01

Debt/Equity

0.11

Debt/Cashflow

-9.51

CUE Investor Care

Shares Dilution (1Y)

12.66%

Diluted EPS (TTM)

-1.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	432.0K	1.8M	3.8M	5.5M
2022	14.4M	11.7M	9.3M	1.2M
2021	3.8M	5.5M	7.2M	14.9M
2020	4.0M	4.0M	3.7M	3.2M
2019	1.7M	2.3M	2.9M	3.5M
2018	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cue Biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 25, 2023	suri anish	bought	11,040	2.76	4,000	president and cso
Aug 14, 2023	passeri daniel r	bought	8,580	2.86	3,000	chief executive officer
Mar 23, 2023	kiener peter a	sold	-30,586	3.28	-9,325	-
Mar 23, 2023	kiener peter a	acquired	27,690	2.86	9,682	-
Aug 22, 2022	millar kerri-ann	sold (taxes)	-8,625	3.05	-2,828	chief financial officer
Aug 21, 2022	millar kerri-ann	acquired	-	-	6,667	chief financial officer
Jun 14, 2022	gray cameron	sold (taxes)	-164,998	3.2	-51,562	-
Jun 14, 2022	gray cameron	acquired	165,000	2.7	61,111	-
May 27, 2022	morich frank	bought	105,000	3.75	28,000	-
May 24, 2022	fletcher aaron g.l.	bought	183,700	3.34	55,000	-

Which funds bought or sold CUE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.19	-11,000	2,000	-%
Apr 18, 2024	SeaCrest Wealth Management, LLC	reduced	-7.14	-12,110	24,570	-%
Apr 15, 2024	Sunbelt Securities, Inc.	unchanged	-	-178	448	-%
Apr 12, 2024	ARMSTRONG ADVISORY GROUP, INC	unchanged	-	-	317	-%
Apr 12, 2024	Gleason Group, Inc.	unchanged	-	-4,500	11,340	-%
Apr 12, 2024	Navalign, LLC	unchanged	-	-18,750	47,250	0.02%
Apr 10, 2024	Wedmont Private Capital	added	100	18,800	76,000	0.01%
Apr 09, 2024	American Capital Advisory, LLC	new	-	2,640	2,640	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	reduced	-25.00	-1,280	7,920	-%

Are Funds Buying or Selling CUE?

Are funds buying CUE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CUE

No. of Funds

Unveiling Cue Biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	bleichroeder lp	6.11%	2,755,028	SC 13G
Feb 07, 2024	blackrock inc.	4.98%	2,247,978	SC 13G
Jan 31, 2024	blackrock inc.	5.2%	2,338,765	SC 13G
Feb 14, 2023	slate path capital lp	5.6%	2,402,455	SC 13G
Feb 03, 2023	state street corp	0.33%	141,153	SC 13G/A
Dec 02, 2022	nantahala capital management, llc	0.3%	93,297	SC 13G/A
Nov 18, 2022	slate path capital lp	5.6%	2,402,455	SC 13G
Jul 08, 2022	blackrock inc.	2.4%	831,925	SC 13G
Feb 14, 2022	nantahala capital management, llc	8.0%	2,539,700	SC 13G/A
Feb 14, 2022	corriente advisors, llc	0.0%	0	SC 13G/A

Recent SEC filings of Cue Biopharma Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	10-K	Annual Report
Mar 11, 2024	SC 13G	Major Ownership Report
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 07, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Cue Biopharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Cue Biopharma Inc News

Latest updates

Cue Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-13.3%	1,821,000	2,100,000	1,382,000	187,000	151,000	68,000	26,000	1,000,000	8,254,370	2,395,000	2,739,000	1,553,000	475,325	704,000	1,075,000	900,000	1,049,331	984,000	1,055,000	370,000	409,500
Operating Expenses	15.8%	15,653,500	13,519,000	14,899,000	13,567,000	15,017,000	11,099,000	13,116,000	15,238,000	16,137,443	15,413,000	13,042,000	14,071,000	11,449,910	10,835,000	12,017,000	13,895,000	10,065,578	8,078,000	10,286,000	11,797,000	11,381,262
S&GA Expenses	26.5%	4,609,500	3,645,000	4,249,000	4,176,000	3,703,500	3,528,000	3,782,000	5,156,000	4,646,678	4,125,000	4,280,000	4,255,000	3,446,205	3,318,000	3,898,000	3,989,000	3,100,593	2,776,000	3,419,000	3,444,000	4,470,711
R&D Expenses	10.3%	10,887,000	9,874,000	10,650,000	9,391,000	11,332,500	7,571,000	9,592,000	10,082,000	11,490,765	11,288,000	8,762,000	9,816,000	8,003,705	7,517,000	8,119,000	9,906,000	6,964,985	5,302,000	6,867,000	8,353,000	6,910,551
EBITDA Margin	30.3%	-9.78	-14.03	-29.85	-123	-42.40	-4.60	-3.66	-2.95	-2.84	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-51.0%	-432,000	-286,000	-232,000	-370,000	-358,000	-124,000	-206,000	-25,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	289,000	-	-	206,000	-	-	-	-	-500	-	413,000	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,896,671	-10,031,000	-10,833,000	-	-8,918,457	-6,990,000	-9,109,000	-	-10,796,313
EBT Margin	30.4%	-9.66	-13.88	-29.64	-122	-42.57	-4.67	-3.74	-3.03	-2.92	-5.68	-7.43	-10.68	-	-	-	-	-	-	-	-	-
Net Income	-22.1%	-13,434,000	-11,005,000	-13,185,000	-13,109,000	-14,592,000	-10,955,000	-13,208,000	-14,255,000	-8,384,175	-12,993,000	-10,279,000	-12,505,000	-11,102,921	-10,031,000	-10,833,000	-12,818,000	-8,918,457	-6,990,000	-9,522,000	-11,267,000	-11,613,813
Net Income Margin	32.0%	-9.24	-13.58	-28.99	-119	-42.57	-5.01	-4.18	-3.19	-2.96	-6.55	-8.03	-11.68	-	-	-	-	-	-	-	-	-
Free Cashflow	-40.5%	-10,958,000	-7,799,000	-10,371,000	-10,833,000	-10,514,700	-6,949,000	-12,913,000	-11,600,000	-10,645,205	-6,640,000	-10,022,000	-12,443,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.7%	62.00	69.00	73.00	82.00	91.00	76.00	85.00	91.00	83.00	79.00	90.00	89.00	100	107	101	61.00	72.00	45.00	42.00	45.00	45.00
Current Assets	-10.5%	51.00	58.00	61.00	69.00	77.00	62.00	69.00	76.00	68.00	70.00	80.00	77.00	88.00	94.00	88.00	51.00	61.00	33.00	30.00	32.00	41.00
Cash Equivalents	-11.3%	49.00	55.00	53.00	56.00	52.00	30.00	66.00	68.00	64.00	68.00	74.00	73.00	75.00	72.00	60.00	23.00	44.00	31.00	24.00	22.00	21.00
Net PPE	-25.3%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00
Liabilities	-6.8%	24.00	26.00	27.00	27.00	26.00	26.00	25.00	26.00	18.00	15.00	17.00	19.00	21.00	19.00	21.00	15.00	17.00	18.00	21.00	20.00	11.00
Current Liabilities	-0.7%	17.00	17.00	16.00	14.00	12.00	10.00	8.00	11.00	13.00	15.00	17.00	17.00	16.00	14.00	15.00	12.00	12.00	10.00	11.00	11.00	6.00
Long Term Debt	-18.6%	4.00	5.00	6.00	7.00	8.00	9.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-18.6%	4.00	5.00	6.00	7.00	8.00	9.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-13.1%	37.00	43.00	46.00	55.00	66.00	51.00	60.00	65.00	65.00	64.00	73.00	70.00	79.00	88.00	80.00	45.00	55.00	27.00	20.00	25.00	34.00
Retained Earnings	-4.7%	-301	-287	-276	-263	-250	-235	-224	-211	-197	-189	-176	-165	-153	-142	-132	-121	-108	-99.58	-92.59	-83.07	-71.80
Additional Paid-In Capital	2.4%	338	330	323	319	316	287	285	276	263	253	249	235	232	230	212	166	163	127	113	108	106
Shares Outstanding	-4.6%	43.00	45.00	44.00	43.00	47.00	34.00	35.00	33.00	32.00	31.00	31.00	30.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	154	-	-	-	82.00	-	-	-	363	-	-	-	695	-	-	-	160	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-40.5%	-10,958	-7,799	-10,371	-10,833	-10,514	-6,871	-12,848	-11,573	-10,645	-6,627	-9,770	-11,795	-6,999	-7,687	-6,864	-10,944	-6,437	-9,208	-6,676	-8,475	-3,897
Share Based Compensation	0.0%	2,072	2,073	2,037	1,998	2,112	2,064	2,309	3,011	2,974	3,252	2,854	2,436	2,282	2,500	2,524	3,175	1,994	1,439	1,321	1,768	2,010
Cashflow From Investing	-100.0%	-	5,000	5,000	15,002	4,999	-29,520	-62.00	-27.00	511*	-11.00	-233	9,352	9,892	4,654	-140	-9,950	-15,145	3,984	5,127	9,481	4,687
Cashflow From Financing	4.2%	4,782	4,589	2,101	388	27,403	-9.00	11,109	15,156	7,382	351	10,666	834	244	15,013	43,321	36.00	34,494	12,292	3,747	257	4,170
Buy Backs	-	-	-	-	-	-	9.00	-	191	183	482	-	85.00	160	35.00	-	-	-	-	-	-	-

CUE Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 5,490	$ 1,245
Operating expenses (income):
General and administrative	16,680	16,169
Research and development	40,802	38,578
Loss (gain) on fixed asset disposal and right-of-use asset termination	157	(277)
Total operating expenses	57,639	54,470
Loss from operations	(52,149)	(53,225)
Other income (expense):
Interest income	2,661	928
Interest expense	(1,245)	(713)
Total other income	1,416	215
Net loss	(50,733)	(53,010)
Unrealized loss from available-for-sale securities	96	(96)
Comprehensive loss	$ (50,637)	$ (53,106)
Net loss per common share - basic	$ (1.11)	$ (1.49)
Net loss per common share - diluted	$ (1.11)	$ (1.49)
Weighted average common shares outstanding, basic	45,754,794	35,649,134
Weighted average common shares outstanding, diluted	45,754,794	35,649,134

CUE Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 48,514,000	$ 51,614,000
Marketable securities	0	24,675,000
Accounts receivable	1,698,000	57,000
Prepaid expenses and other current assets	1,242,000	841,000
Total current assets	51,454,000	77,187,000
Property and equipment, net	795,000	1,499,000
Operating lease right-of-use assets	6,323,000	9,203,000
Deposits	2,690,000	3,116,000
Restricted cash	151,000	150,000
Other long term assets	117,000	128,000
Total assets	61,530,000	91,283,000
Current liabilities:
Accounts payable	3,501,000	2,731,000
Accrued expenses	4,137,000	3,554,000
Research and development contract liability, current portion	2,112,000	0
Operating lease liabilities, current portion	3,368,000	3,300,000
Current portion of long-term debt, net	3,963,000	1,963,000
Total current liabilities	17,081,000	11,548,000
Operating lease liabilities, net of current portion	3,162,000	6,018,000
Long-term debt, net	4,202,000	8,035,000
Total liabilities	24,445,000	25,601,000
Commitments and contingencies (NOTE 15)
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized – 10,000,000 shares; issued and outstanding – none	0	0
Common stock, $0.001 par value; authorized - 100,000,000 shares; issued and outstanding - 43,042,548 shares and 43,042,548 shares at December 31, 2023 and 2022, respectively	47,000	43,000
Additional paid in capital	338,228,000	316,192,000
Accumulated other comprehensive income	0	(96,000)
Accumulated deficit	(301,190,000)	(250,457,000)
Total stockholders’ equity	37,085,000	65,682,000
Total liabilities and stockholders’ equity	$ 61,530,000	$ 91,283,000

About Cue Biopharma Inc

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CEO	Mr. Daniel R. Passeri J.D., M.Sc., MSc.
WEBSITE	cuebiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	51

Cue Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Cue Biopharma Inc? What does CUE stand for in stocks?

CUE is the stock ticker symbol of Cue Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cue Biopharma Inc (CUE)?

As of Wed Apr 24 2024, market cap of Cue Biopharma Inc is 69.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers. The fair value of Cue Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cue Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cue Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether CUE is over valued or under valued. Whether Cue Biopharma Inc is cheap or expensive depends on the assumptions which impact Cue Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CUE.

What is Cue Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, CUE's PE ratio (Price to Earnings) is -1.36 and Price to Sales (PS) ratio is 12.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CUE PE ratio will change depending on the future growth rate expectations of investors.